Stephens Inc. AR Trims Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)

Stephens Inc. AR trimmed its holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) by 4.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,439 shares of the company’s stock after selling 656 shares during the period. Stephens Inc. AR owned approximately 0.05% of Castle Biosciences worth $385,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Connor Clark & Lunn Investment Management Ltd. grew its stake in Castle Biosciences by 147.4% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 165,458 shares of the company’s stock valued at $4,719,000 after buying an additional 98,571 shares in the last quarter. Harbor Capital Advisors Inc. grew its position in shares of Castle Biosciences by 11.0% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 153,907 shares of the company’s stock valued at $4,389,000 after purchasing an additional 15,200 shares in the last quarter. Barclays PLC grew its position in shares of Castle Biosciences by 310.7% during the 3rd quarter. Barclays PLC now owns 52,301 shares of the company’s stock valued at $1,491,000 after purchasing an additional 39,567 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Castle Biosciences by 165.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 69,409 shares of the company’s stock valued at $1,980,000 after purchasing an additional 43,241 shares in the last quarter. Finally, GSA Capital Partners LLP purchased a new position in shares of Castle Biosciences during the 3rd quarter valued at $1,478,000. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

CSTL has been the subject of a number of recent analyst reports. Stephens restated an “overweight” rating and set a $41.00 price target on shares of Castle Biosciences in a research report on Thursday, January 2nd. Canaccord Genuity Group boosted their price target on shares of Castle Biosciences from $35.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, October 29th. Robert W. Baird boosted their price target on shares of Castle Biosciences from $37.00 to $39.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. Scotiabank boosted their price target on shares of Castle Biosciences from $37.00 to $44.00 and gave the company a “sector outperform” rating in a research report on Wednesday, November 6th. Finally, Lake Street Capital upped their target price on shares of Castle Biosciences from $34.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $40.29.

Castle Biosciences Stock Down 1.1 %

Shares of NASDAQ:CSTL opened at $27.32 on Friday. The firm has a fifty day moving average of $27.83 and a 200 day moving average of $29.10. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.64 and a current ratio of 7.78. Castle Biosciences, Inc. has a 52-week low of $16.97 and a 52-week high of $35.84. The firm has a market capitalization of $765.23 million, a PE ratio of 136.61 and a beta of 0.91.

Insider Buying and Selling at Castle Biosciences

In other news, Director Daniel Bradbury sold 7,867 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $29.14, for a total transaction of $229,244.38. Following the completion of the transaction, the director now directly owns 1,425 shares of the company’s stock, valued at approximately $41,524.50. This represents a 84.66 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Derek J. Maetzold sold 9,364 shares of the company’s stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $28.34, for a total transaction of $265,375.76. Following the transaction, the insider now directly owns 84,762 shares of the company’s stock, valued at approximately $2,402,155.08. This trade represents a 9.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,771 shares of company stock worth $886,112 over the last three months. Company insiders own 7.20% of the company’s stock.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.